Harvard Bioscience Inc (HBIO)

Currency in USD
0.483
+0.004(+0.84%)
Closed·
0.464-0.019(-3.83%)
·
HBIO Scorecard
Full Analysis
Management has been aggressively buying back shares
HBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.4680.500
52 wk Range
0.2813.270
Key Statistics
Prev. Close
0.483
Open
0.471
Day's Range
0.468-0.5
52 wk Range
0.281-3.27
Volume
541.89K
Average Volume (3m)
11.94M
1-Year Change
-83.63%
Book Value / Share
0.36
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.000
Upside
+521.12%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Harvard Bioscience Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Harvard Bioscience Inc Company Profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Harvard Bioscience Inc Earnings Call Summary for Q2/2025

  • Q2 revenue of $20.5M missed forecast; EPS at -$0.01 below expectations. Net debt reduced to $27.9M. Stock resilient despite mixed results.
  • Adjusted EBITDA improved to $1.5M from $1.3M YoY. Gross margin slightly down at 56.4%. Operating cash flow at $2.8M.
  • Q3 revenue guidance: $19-$21M. Gross margin guidance: 56-58%. Company optimistic about NIH funding and academic purchasing in 2026.
  • New product launches, including SOHO telemetry platform and MeSH MEA organoid platform expansion, expected to drive future growth.
  • CEO emphasized focus on debt restructuring and balance sheet investment. Expressed confidence in overcoming market uncertainties.
Last Updated: 11/08/2025, 13:50
Read Full Transcript

Compare HBIO to Peers and Sector

Metrics to compare
HBIO
Peers
Sector
Relationship
P/E Ratio
−0.4x−1.9x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
1.4x1.4x2.6x
Price / LTM Sales
0.2x2.9x3.3x
Upside (Analyst Target)
-53.2%41.6%
Fair Value Upside
Unlock22.0%5.9%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.000
(+521.12% Upside)

Earnings

Latest Release
Aug 11, 2025
EPS / Forecast
-0.01 / -0.005
Revenue / Forecast
20.45M / 21.40M
EPS Revisions
Last 90 days

HBIO Income Statement

People Also Watch

18.80
SRPT
+4.79%
4.5500
BTCS
-1.09%
1.230
SQNS
-4.65%
1.660
VOR
-16.58%

FAQ

What Stock Exchange Does Harvard Bioscience Trade On?

Harvard Bioscience is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Harvard Bioscience?

The stock symbol for Harvard Bioscience is "HBIO."

What Is the Harvard Bioscience Market Cap?

As of today, Harvard Bioscience market cap is 21.49M.

What Is Harvard Bioscience's Earnings Per Share (TTM)?

The Harvard Bioscience EPS (TTM) is -1.31.

When Is the Next Harvard Bioscience Earnings Date?

Harvard Bioscience will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is HBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Harvard Bioscience Stock Split?

Harvard Bioscience has split 0 times.

How Many Employees Does Harvard Bioscience Have?

Harvard Bioscience has 343 employees.

What is the current trading status of Harvard Bioscience (HBIO)?

As of 13 Aug 2025, Harvard Bioscience (HBIO) is trading at a price of 0.48, with a previous close of 0.48. The stock has fluctuated within a day range of 0.47 to 0.50, while its 52-week range spans from 0.28 to 3.27.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.